# A web-based, peer-supported self-management intervention to reduce distress in relatives of people with psychosis or bipolar disorder: the REACT RCT

Fiona Lobban, 1\* Nadia Akers, 1 Duncan Appelbe, 2 Rossella Iraci Capuccinello, 3 Lesley Chapman, 1 Lizzi Collinge, 1 Susanna Dodd, 2 Sue Flowers, 1 Bruce Hollingsworth, 3 Mahsa Honary, 1 Sonia Johnson, 4 Steven H Jones, 1 Ceu Mateus, 3 Barbara Mezes, 1 Elizabeth Murray, 5 Katerina Panagaki, 1 Naomi Rainford, 2 Heather Robinson, 1 Anna Rosala-Hallas, 2 William Sellwood, 3 Andrew Walker 1 and Paula R Williamson 2

**Declared competing interests of authors:** Fiona Lobban reports grants from the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme during the conduct of the study. Fiona Lobban and Lesley Chapman were involved in the design and development of the Relatives' Education And Coping Toolkit (REACT); hence, this is not an independent evaluation. Bruce Hollingsworth reports that he was a NIHR Health Services and Delivery Research Commissioned Board member (2013–15). Paula Williamson reports grants from NIHR during the conduct of the study, and that the Clinical Trials Research Centre at the University of Liverpool was in receipt of NIHR Support Funding during the conduct of the study.

**Disclaimer:** This report contains transcripts of interviews conducted in the course of the research and contains language that may offend some readers.

<sup>&</sup>lt;sup>1</sup>Spectrum Centre for Mental Health Research, Division of Health Research, Faculty of Health and Medicine, Lancaster University, Lancaster, UK

<sup>&</sup>lt;sup>2</sup>Clinical Trials Research Centre, Department of Biostatistics, University of Liverpool (a member of Liverpool Health Partners), Liverpool, UK

<sup>&</sup>lt;sup>3</sup>Division of Health Research, Faculty of Health and Medicine, Lancaster University, Lancaster, UK

<sup>&</sup>lt;sup>4</sup>Division of Psychiatry, University College London, London, UK

<sup>&</sup>lt;sup>5</sup>Research Department of Primary Care and Population Health, University College London, London, UK

<sup>\*</sup>Corresponding author f.lobban@lancaster.ac.uk

Published June 2020 DOI: 10.3310/hta24320

# **Scientific summary**

## The REACT RCT

Health Technology Assessment 2020; Vol. 24: No. 32

DOI: 10.3310/hta24320

NIHR Journals Library www.journalslibrary.nihr.ac.uk

# Scientific summary

#### **Background**

Relatives supporting people with a severe mental health problem, such as psychosis or bipolar disorder, face many challenges and report high levels of distress. Psychoeducation and emotional support through peer interactions are effective, beneficial and recommended by the National Institute for Health and Care Excellence. However, evidence shows that many relatives are unable to access these services. The Relatives' Education And Coping Toolkit (REACT) was an online, supported self-management package designed to improve availability and access to support for relatives. It included a comprehensive online resource directory.

### **Objectives**

The aim of the trial was to determine the clinical effectiveness and cost-effectiveness of REACT with the resource directory and treatment as usual, compared with only the resource directory and treatment as usual. This was the first definitive randomised controlled trial to test an online digital health intervention for relatives of people with severe mental health problems.

The objectives were to determine the:

- impact of REACT on relatives' distress
- impact of REACT on relatives' well-being and support
- impact of REACT on hypothesised mediators of change including relatives' beliefs, perceived coping and amount of use of REACT
- costs associated with delivery and maintenance of REACT
- incremental cost-effectiveness ratio of REACT.

The primary hypothesis was that there would be a significant difference (p < 0.05) between the two arms of the trial in levels of relatives' distress at the 24-week follow-up.

#### **Methods**

The design was an online, single-blinded, two-arm randomised controlled trial.

Eligible participants were relatives or close friends engaged in caring for a person with psychosis or bipolar disorder. Inclusion criteria were as follows: aged  $\geq 16$  years, living in the UK, currently experiencing high levels of distress as a result of their caring role (assessed using a single item from the General Health Questionnaire-28 items, 'Being strung-up and nervous all the time', which required a response of 'rather more than usual' or 'much more than usual' for eligibility), actively seeking help, access to an internet-enabled computer and sufficient command of English to use REACT (which was available only in English). Only one relative per family could take part, and relatives living in any of six geographical areas taking part in a parallel implementation study [the IMPlementation of A Relatives' Toolkit (IMPART) study] of the same intervention were excluded by postcode.

REACT included 12 psychoeducation modules addressing key questions identified by relatives, peer support through a moderated group forum, a confidential direct messaging service and the resource directory of contact details for national organisations offering relevant support.

Relatives with lived experience of supporting someone with a mental health problem were trained to moderate the forum, respond to confidential messages from users and guide users to relevant parts of the toolkit and/or other resources as appropriate. The toolkit was hosted by one NHS mental health trust in England, but was available to relatives across the UK.

The comparator intervention was access to the same resource directory. All trial participants received treatment as usual.

Participants were recruited through mental health services, charities, media, social media and online advertisements. After providing informed consent and baseline data, eligible participants were randomised, using a 1:1 ratio, to 'REACT (including the resource directory) plus treatment as usual' or to 'the resource directory plus treatment as usual', using web-based variable block randomisation, in which the unit of randomisation was the relative. Following randomisation, participants received an e-mail telling them which arm of the trial they had been allocated to. The e-mail included a link to the REACT website, and their username and password. All accounts were set up on the same website, but those in the resource directory-only arm had access only to the directory. All participants were aware that the resource directory was one component of the REACT intervention; therefore, they were likely to have perceived REACT as the 'intervention of interest' and the resource directory as the comparator.

All outcomes were validated self-report measures, collected online using a closed system available only to participants with an account on the REACT website. We gave participants shopping vouchers at each time point as an incentive to complete the follow-up measures.

The primary outcome was relatives' distress at 24 weeks, assessed using an online version of the General Health Questionnaire-28 items, with Likert scoring. Based on our previous feasibility trial, and accounting for design changes and dropout, we aimed to recruit 666 relatives to provide 90% power to reject the null hypothesis (p < 0.05), assuming an estimated mean difference of 5.0 units on the General Health Questionnaire-28 items (standard deviation 16.6 units) and 30% dropout by 24 weeks.

Secondary outcomes included the relatives' well-being and experience of support, assessed online using the Carer Well-being and Support questionnaire at 12 and 24 weeks, and distress (measured using the General Health Questionnaire-28 items) at 12 weeks' follow-up. Illness perceptions (assessed using a modified version of the Brief Illness Perception Questionnaire) and coping (assessed using the Brief Coping Orientation to Problems Experienced) were hypothesised mediators of the intervention effect. The costs of health and personal social care use were assessed using a modified version of the Client Service Receipt Inventory, and quality of life was assessed using the EuroQol-5 Dimensions, five-level version, at baseline and at 12 and 24 weeks.

Mean scores were compared between arms using analysis of covariance, adjusting for baseline scores. A joint modelling approach was used to assess differences in longitudinal outcomes between the randomised arms, adjusted for missingness (at 12-week or 24-week follow-ups). Multivariate analysis of covariance was used for exploratory analyses of the impact of intervention arm on each subscale of the mediator measures, while taking into account correlation between the subscales. Instrumental variable regression was used to estimate the impact of intervention use on outcome. Further exploratory analyses assessed the impact of reading but not posting (known as 'lurking') on the REACT forum.

Participants' experiences of using REACT were explored quantitatively (all participants were in the REACT arm) and qualitatively (purposive sample of 24 participants in the REACT arm). Adverse events were closely monitored. A full statistical analysis plan was published prior to any data analysis.

#### **Results**

The total number of visits to the REACT trial page during the trial was 51,832. The total number of visits to the registration page was 4348. Of the 3287 people who completed the eligibility screening, 1416 failed on at least one of the eligibility criteria, with 1146 (81%) of these failing to report higher than usual levels of distress. Of the 1528 (46%) who subsequently provided consent for the study, 807 completed baseline measures and 800 (52% of those consenting) were randomised. Of these, 424 (53%) were recruited through primarily online strategies [Facebook (Facebook, Inc., Menlo Park, CA, USA) advertising being the most successful], and 376 (47%) were recruited through primarily offline strategies (mainly via mental health services).

Participants were typically middle-aged (40–60 years: n = 422, 53%), white British (n = 727, 91%), female (n = 648, 81%), mothers (n = 387, 48%), highly educated (university level: n = 437, 55%) and supporting an adult aged < 35 years (n = 485, 61%). More than half of participants (n = 462, 58%) were supporting someone with bipolar disorder. Most were supporting only one person, but 209 (26%) reported supporting two or more people, and the majority (n = 457, 57%) also had other dependants. A total of 485 (61%) were married or in a civil partnership. The majority of relatives were in full-time, part-time or voluntary work (n = 512, 64%), but 66 (8.5%) reported being unable to work specifically because of their caring responsibilities. The vast majority had home internet access (n = 795, 99%). Retention was 74% at 12 weeks and 75% at 24 weeks.

Taking into account the full costs of development and delivery, REACT cost £142.95 per person, and the resource directory cost only £0.84 per person. Most of these costs were development; ongoing delivery would cost £62.27 for REACT and £0.43 for the resource directory.

The median time spent on REACT in the REACT arm was 50.8 minutes (interquartile range 12.4–172.1 minutes, range 0.1–4505.5 minutes). The median time spent on the resource directory was 0.5 minutes (interquartile range 0–1.6 minutes, range 0–42.9 minutes). Both online interventions (REACT and the resource directory) were accessed considerably more outside the working week (09.00–17.00, Monday–Friday, excluding public holidays) than during working hours, suggesting a need for online interventions to be available 24 hours a day. The most popular module (with most people visiting at least once) was the online forum.

Relatives had high levels of distress (measured using the General Health Questionnaire-28 items) at baseline (mean score 40.2, standard deviation 14.3), which decreased in both arms by the 24-week follow-up (overall mean score 30.5, standard deviation 15.6), but there was no significant difference between the two arms (-1.39, 95% confidence interval -3.60 to 0.83; p=0.22). At 12 weeks' follow-up, the General Health Questionnaire-28 items scores were lower in the REACT arm than in the resource directory arm (-2.08, 95% confidence interval -4.14 to -0.03); although statistically significant (p=0.027), this was likely to be of limited clinical significance. After accounting for missing data in a longitudinal model, there was no significant difference between REACT and resource directory arms over the 24-week follow-up period (-0.56, 95% confidence interval -2.34 to 1.22; p=0.51). Participants in the REACT arm who dropped out were, on average, 0.33 General Health Questionnaire-28 items units (95% confidence interval -0.27 to 0.93; p=0.279) more distressed than those who remained. Being male, single and unemployed (or in unpaid work) were all associated with greater levels of distress.

Carer well-being and support both increased significantly over time in both arms. There were no significant differences between arms in well-being at either 12 weeks (1.53, 95% confidence interval -2.21 to 5.27; p = 0.42) or 24 weeks (2.39, 95% confidence interval -1.76 to 6.54; p = 0.26). Relatives in the REACT arm reported higher levels of support at 12 weeks (2.50, 95% confidence interval 0.87 to 4.12; p < 0.0001) and at 24 weeks (1.65, 95% confidence interval 0.04 to 3.27; p = 0.045). However, after accounting for missing data in a longitudinal model, the mean difference (1.51, 95% confidence interval -0.005 to 3.01) was no longer statistically significant (p = 0.051) and was likely to be of limited clinical significance.

The within-trial health economic analysis of NHS, health and Personal Social Services outcomes found REACT to have higher costs (of £286.77, 95% confidence interval -£858.81 to £1432.36; p = 0.624), slightly better General Health Questionnaire-28 items scores (incremental General Health Questionnaire-28 items scores adjusted for baseline General Health Questionnaire-28 items score, age and gender -1.152, 95% confidence interval -3.370 to 1.065) and slightly lower quality-adjusted life-year gains (incremental quality-adjusted life-years adjusted for baseline EuroQol-5 Dimensions, five-level version, index score; age; and gender -0.0024, 95% confidence interval -0.0088 to 0.0039) than the resource directory only, but none of these differences was statistically significant.

Illness perceptions and perceived coping improved over time. However, neither had a significant mediation effect on outcome. There was no evidence of a causal association between amount of use of REACT and impact on outcomes. The REACT forum users were estimated to have lower General Health Questionnaire-28 items scores at 24 weeks than non-users (-2.0, 95% confidence interval -5.9 to 1.9), who had similar outcomes to people reading but not posting ('lurkers') (-0.1, 95% confidence interval -3.2 to 2.9); however, there was no evidence of a significant difference (p = 0.59).

The intervention appeared highly acceptable. Participants reported finding REACT a safe and confidential environment (96%), feeling supported by the REACT arm (89%) and by the REACT supporters (86%). There were no serious adverse events (i.e. immediate and serious risk to life or to child welfare). Qualitative feedback was extremely positive. REACT was particularly valued by relatives for being comprehensive, relevant, easy to access, private and anonymous. The proactive support from the REACT supporters was appreciated, as was the opportunity to learn, through a variety of different media (e.g. text, video, forum), how best to support someone with a mental health problem. However, a consistent message was that REACT would be most useful to relatives early in the recovery journey, when they were likely to seek information and strategies. Some relatives found seeking help for their own needs difficult, and most relatives found prioritising time to use the REACT difficult. The advantage of online interventions is that they are conveniently accessible at any time, but the challenge is to make time to use them.

#### Conclusions

Relatives felt safe and well supported using REACT, which might facilitate better engagement with other aspects of the service. Key developments should include the following: redesigning the content and presentation using feedback from participants; making the technology more interactive and user friendly; increasing the role of the REACT supporters to include support to use the modules; specifying recommended levels of use; and offering REACT to relatives earlier in the recovery journey, alongside other components of care, particularly for those with high levels of distress.

#### Recommendations for further research

- Given the apparent unmet need and high acceptability of REACT, further work is needed to make the content of REACT more effective.
- Psychoeducation and support are important and valued by relatives, but distress (measured by the
  General Health Questionnaire-28 items) may not be the most appropriate outcome for evaluating their
  effectiveness. Understanding more about a chronic health problem for which there is no immediate
  cure is important, but is unlikely to reduce distress without additional therapeutic input. Therefore, the
  effectiveness of psychoeducation interventions may be better tested against alternative outcomes, such
  as supporting relatives to feel more knowledgeable, more empowered, better able to cope and more
  engaged with services, rather than on reducing distress.
- Research is needed to understand how to increase engagement and use of REACT (and other digital health interventions) to maximise their potential to improve outcomes.

- Research is needed to understand how to improve uptake and reach of REACT (and other digital health interventions) by groups that currently show low levels of use of mental health and support services, including ethnic minority groups and men.
- The impact of psychoeducation interventions for relatives on service user outcomes needs to be tested.
- Randomised controlled trials can be delivered online at lower cost. However, this methodology
  presents new challenges in keeping participants engaged throughout long-term follow-ups, and in
  managing high-quality patient and public involvement. Both require further research.

## **Trial registration**

This trial is registered as ISRCTN72019945.

#### **Funding**

This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in *Health Technology* Assessment; Vol. 24, No. 32. See the NIHR Journals Library website for further project information.

# **Health Technology Assessment**

ISSN 1366-5278 (Print)

ISSN 2046-4924 (Online)

Impact factor: 3.819

Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, the Cochrane Library and Clarivate Analytics Science Citation Index.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

Editorial contact: journals.library@nihr.ac.uk

The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk

#### Criteria for inclusion in the Health Technology Assessment journal

Reports are published in *Health Technology Assessment* (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in *Health Technology Assessment* are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

#### **HTA** programme

Health Technology Assessment (HTA) research is undertaken where some evidence already exists to show that a technology can be effective and this needs to be compared to the current standard intervention to see which works best. Research can evaluate any intervention used in the treatment, prevention or diagnosis of disease, provided the study outcomes lead to findings that have the potential to be of direct benefit to NHS patients. Technologies in this context mean any method used to promote health; prevent and treat disease; and improve rehabilitation or long-term care. They are not confined to new drugs and include any intervention used in the treatment, prevention or diagnosis of disease.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

#### This report

The research reported in this issue of the journal was funded by the HTA programme as project number 14/49/34. The contractual start date was in October 2015. The draft report began editorial review in February 2019 and was accepted for publication in November 2019. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care.

© Queen's Printer and Controller of HMSO 2020. This work was produced by Lobban et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).

#### Editor-in-Chief of **Health Technology Assessment** and NIHR Journals Library

Professor Ken Stein Professor of Public Health, University of Exeter Medical School, UK

#### **NIHR Journals Library Editors**

**Professor John Powell** Chair of HTA and EME Editorial Board and Editor-in-Chief of HTA and EME journals. Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK, and Senior Clinical Researcher, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK

**Professor Andrée Le May** Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals) and Editor-in-Chief of HS&DR, PGfAR, PHR journals

**Professor Matthias Beck** Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

Dr Tessa Crilly Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin Senior Scientific Advisor, Wessex Institute, UK

Dr Peter Davidson Consultant Advisor, Wessex Institute, University of Southampton, UK

Ms Tara Lamont Director, NIHR Dissemination Centre, UK

Dr Catriona McDaid Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

Professor William McGuire Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads Professor of Wellbeing Research, University of Winchester, UK

Professor John Norrie Chair in Medical Statistics, University of Edinburgh, UK

**Professor James Raftery** Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts Professor of Child Health Research, UCL Great Ormond Street Institute of Child Health, UK

Professor Jonathan Ross Professor of Sexual Health and HIV, University Hospital Birmingham, UK

**Professor Helen Snooks** Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Ken Stein Professor of Public Health, University of Exeter Medical School, UK

**Professor Jim Thornton** Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Professor Martin Underwood Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of editors: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: journals.library@nihr.ac.uk